Russian Vaccine is Launched Globally
Presentation of the Russian Ebola vaccine has been held in Geneva. Vaccine development was performed by Russian scientists for over one year – from Autumn 2014. A few mechanisms of vector vaccine development were used. For 15 months two Russian vaccines showed maximum efficacy with complete safety and good tolerability. Created by genetic engineering (without live virus) these vaccines stimulate development of antigen preventing infection.
In 2015 preclinical studies were held in small animals. Then a series of phase 1 and 2 clinical studies was held, conducted with participation of healthy volunteers at the Gamaleya institute.
Speaking at the presentation, Minister of healthcare of the Russian Federation Veronika Skvortsova told about results of preclinical and clinical trials. “Currently, she remarked, that at the press-conference in Geneva all immunized persons and subjects who completed phase one and two studies are followed up. We can say that 4.5 – 5 months after immunization they still retained high titer of antibodies against Ebola hemorrhagic fever”.
Two vaccines against Ebola fever are already approved in the Russian Federation. It is planned to supply the vaccine to Guinea, where in cooperation with National Pasteur Institute Russian epidemiologists will perform comparative studies of our vaccine with similar foreign drugs.